Forbes December 7, 2023
The Biden Administration says it seeks to use march-in-rights for certain prescription drugs to lower prices. Today it unveiled a roadmap that would allow the federal government to grant licenses to third parties for products developed using federal funds if the original patent holder does not make them available to the public on “reasonable terms.” It’s unclear, however, which drugs would meet the standard of “reasonable terms.”
On X (formerly known as Twitter) President Biden posted that his Administration is “proposing that if a drug made using taxpayer funds is not reasonably available to Americans, the government reserves the right to “march in” and license that drug to another manufacturer who could sell it for less.”
The Administration issued a...
Today's Sponsors
Today's Sponsor